DE69620169D1 - Zusammensetzungen zur penetrationsförderung in der haut durch gebrauch von acryllactylaten - Google Patents

Zusammensetzungen zur penetrationsförderung in der haut durch gebrauch von acryllactylaten

Info

Publication number
DE69620169D1
DE69620169D1 DE69620169T DE69620169T DE69620169D1 DE 69620169 D1 DE69620169 D1 DE 69620169D1 DE 69620169 T DE69620169 T DE 69620169T DE 69620169 T DE69620169 T DE 69620169T DE 69620169 D1 DE69620169 D1 DE 69620169D1
Authority
DE
Germany
Prior art keywords
drug
permeation enhancer
compositions
skin
lactylates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69620169T
Other languages
English (en)
Other versions
DE69620169T2 (de
Inventor
Soo Lee
Ii Yum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE69620169D1 publication Critical patent/DE69620169D1/de
Application granted granted Critical
Publication of DE69620169T2 publication Critical patent/DE69620169T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
DE69620169T 1995-05-26 1996-05-13 Zusammensetzungen zur penetrationsförderung in der haut durch gebrauch von acryllactylaten Expired - Lifetime DE69620169T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/452,468 US5882676A (en) 1995-05-26 1995-05-26 Skin permeation enhancer compositions using acyl lactylates
PCT/US1996/006868 WO1996037231A1 (en) 1995-05-26 1996-05-13 Skin permeation enhancer compositions using acyl lactylates

Publications (2)

Publication Number Publication Date
DE69620169D1 true DE69620169D1 (de) 2002-05-02
DE69620169T2 DE69620169T2 (de) 2002-12-19

Family

ID=23796563

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620169T Expired - Lifetime DE69620169T2 (de) 1995-05-26 1996-05-13 Zusammensetzungen zur penetrationsförderung in der haut durch gebrauch von acryllactylaten

Country Status (13)

Country Link
US (1) US5882676A (de)
EP (1) EP0828516B1 (de)
JP (1) JP4086897B2 (de)
KR (1) KR100445449B1 (de)
CN (1) CN1107522C (de)
AT (1) ATE214946T1 (de)
AU (1) AU697200B2 (de)
CA (1) CA2217029A1 (de)
DE (1) DE69620169T2 (de)
DK (1) DK0828516T3 (de)
ES (1) ES2171672T3 (de)
MX (1) MX9709162A (de)
WO (1) WO1996037231A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5676648A (en) 1996-05-08 1997-10-14 The Aps Organization, Llp Iontophoretic drug delivery apparatus and method for use
US6385487B1 (en) 1996-05-08 2002-05-07 Biophoretic Therapeutic Systems, Llc Methods for electrokinetic delivery of medicaments
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
CA2263334A1 (en) * 1996-10-30 1998-05-07 Sonal R. Patel Fatty acid esters of lactic acid salts as permeation enhancers
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
USRE37796E1 (en) 1997-12-16 2002-07-23 Biophoretic Therapeutic Systems, Llc Methods for iontophoretic delivery of antiviral agents
WO1999032153A1 (en) * 1997-12-22 1999-07-01 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
IL141095A0 (en) * 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6148231A (en) * 1998-09-15 2000-11-14 Biophoretic Therapeutic Systems, Llc Iontophoretic drug delivery electrodes and method
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7127285B2 (en) * 1999-03-12 2006-10-24 Transport Pharmaceuticals Inc. Systems and methods for electrokinetic delivery of a substance
US6792306B2 (en) * 2000-03-10 2004-09-14 Biophoretic Therapeutic Systems, Llc Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
US6477410B1 (en) 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
DE19918105C1 (de) * 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DK1328273T3 (da) * 2000-10-23 2008-10-20 Euro Celtique Sa Anordning og fremgangsmåder til transdermal indgivelse af felodipin
US7018649B2 (en) 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
ES2270746T3 (es) * 2001-03-16 2007-12-01 Alza Corporation Parche transdermico para administrar fentanilo.
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
JP2005526839A (ja) * 2002-04-23 2005-09-08 アルザ・コーポレーシヨン 不正使用の可能性が低い経皮鎮痛薬システム
PT1513532E (pt) 2002-06-10 2007-05-31 Euro Celtique Sa Sistemas para eliminar dispositivos de veiculação transdérmica para impedir uma má utilização dos agentes activos neles contidos
WO2004017941A2 (en) * 2002-08-20 2004-03-04 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
DE60325486D1 (de) 2002-08-30 2009-02-05 Alza Corp Prägbare und beschreibbare verbundrückschicht
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1651197A1 (de) 2003-07-28 2006-05-03 ALZA Corporation Transdermales warfarin enthaltendes abgabesystem
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
WO2005044243A2 (en) 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
EP1802258A4 (de) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchrone transdermale arzneiabgabe
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CN100425233C (zh) * 2005-01-12 2008-10-15 复旦大学 一种鼻腔用尼莫地平凝胶剂
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
EP2316437B1 (de) * 2005-05-13 2014-07-30 Alza Corporation Mehrschichtiges Arzneimittelabgabesystem mit Barriere gegen Reservoirmaterialfluss
WO2007011763A2 (en) * 2005-07-15 2007-01-25 3M Innovative Properties Company Adhesive sheet and methods of use thereof
JPWO2007010900A1 (ja) * 2005-07-15 2009-01-29 Ｔｔｉ・エルビュー株式会社 貼付位置表示機能付き経皮吸収用パッチ及びイオントフォレーシス装置
US20070134310A1 (en) * 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
EP1937226A2 (de) * 2005-09-23 2008-07-02 Alza Corporation Transdermales galantaminzufuhrsystem
US20070098772A1 (en) * 2005-09-23 2007-05-03 Westcott Tyler D Transdermal norelgestromin delivery system
EP2308480B1 (de) 2005-09-23 2014-08-13 ALZA Corporation Polyacrylatformulierung mit hoher Beladung von verstärkenden Substanzen für transdermale Anwendungen
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
WO2007079193A2 (en) 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
JPWO2008087803A1 (ja) * 2007-01-16 2010-05-06 国立大学法人北海道大学 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
RU2499583C2 (ru) * 2007-10-15 2013-11-27 Алза Корпорейшн Заместительное трансдермальное введение фентанила один раз в день
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100069877A1 (en) * 2008-09-10 2010-03-18 Smith Gregory A Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process
US8236862B2 (en) * 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
CA2775676C (en) 2009-09-28 2016-08-16 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
EP2542082B8 (de) 2010-03-03 2020-06-17 Neonc Technologies Inc. PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT (S)-Perillylalkohol
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104955516B (zh) * 2012-12-28 2019-01-22 帝国制药美国公司 延长丁丙诺啡经皮递送组合物及其使用方法
EP3146964A4 (de) * 2014-05-20 2018-01-10 Alcare Co., Ltd. Klebmittelzusammensetzung für haut und pflastermaterial für haut
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US20210228498A1 (en) 2018-02-08 2021-07-29 Neonc Technologies, Inc. Methods of permeabilizing the blood brain barrier
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
CN109700601B (zh) * 2019-02-02 2022-04-22 天津嘉氏堂科技有限公司 一种水胶体硅敷料贴
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1001949B (de) * 1953-03-13 1957-01-31 Escher Wyss Gmbh Einrichtung zur Verhinderung von Kavitationserscheinungen an der Laufradnabe von Kaplanturbinen
US3527864A (en) * 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3903256A (en) * 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) * 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) * 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4130667A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4184978A (en) * 1977-05-04 1980-01-22 C. J. Patterson Company Stable water in oil emulsion systems for cosmetic and pharmaceutical preparations
US4301820A (en) * 1980-02-04 1981-11-24 Redken Laboratories, Inc. Permanent waving compositions containing fatty acid lactylates and glycolates and their method of use
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
DE8507337U1 (de) * 1985-03-13 1991-02-28 Schlafhorst Ag & Co
US4702916A (en) * 1985-12-03 1987-10-27 Warner-Lambert Company Analgesic stick compositions
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4822601A (en) * 1987-03-13 1989-04-18 R.I.T.A. Corporation Cosmetic base composition with therapeutic properties
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
GB8913708D0 (en) * 1989-06-14 1989-08-02 Unilever Plc Cosmetic composition
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
GB9211428D0 (en) * 1992-05-29 1992-07-15 Unilever Plc Acyl lactylates as antimicrobial actives
AU668559B2 (en) * 1992-06-03 1996-05-09 Unilever Plc Improvements relating to cosmetic compositions
GB2273044B (en) * 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
US5344651A (en) * 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
EP0793481B1 (de) * 1993-08-13 2004-06-02 Unilever Plc Kosmetische zusammensetzung enthaltend hydroxyalkanoat derivate
KR960704579A (ko) * 1993-09-29 1996-10-09 에드워드 엘. 만델 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin)
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination

Also Published As

Publication number Publication date
CN1107522C (zh) 2003-05-07
CA2217029A1 (en) 1996-11-28
US5882676A (en) 1999-03-16
WO1996037231A1 (en) 1996-11-28
EP0828516A1 (de) 1998-03-18
CN1185741A (zh) 1998-06-24
MX9709162A (es) 1998-03-31
ATE214946T1 (de) 2002-04-15
AU697200B2 (en) 1998-10-01
KR19990021986A (ko) 1999-03-25
ES2171672T3 (es) 2002-09-16
KR100445449B1 (ko) 2004-10-14
EP0828516B1 (de) 2002-03-27
JP4086897B2 (ja) 2008-05-14
DK0828516T3 (da) 2002-07-22
AU5792896A (en) 1996-12-11
JPH11505843A (ja) 1999-05-25
DE69620169T2 (de) 2002-12-19

Similar Documents

Publication Publication Date Title
DE69620169T2 (de) Zusammensetzungen zur penetrationsförderung in der haut durch gebrauch von acryllactylaten
ATE185694T1 (de) Oxybutynin zur transdermalen verabreichung
DK0934078T3 (da) Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf
DE69401945T2 (de) Einarbeitung eines poly-n-vinylamids in ein transdermales system
DE69637061D1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
EP0561983A4 (en) Method and systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers
DK0388306T3 (da) Farmaceutisk præparat til behandling af smerte knyttet til herpes zoster og postherpetisk neuralgi ved topisk påføring af l
EP0164998A3 (de) Mittel und Verfahren zur Erhöhung der transdermalen und transmembranen Penetration topischer und systemischer Wirkstoffe
ATE322272T1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetin
TWI265027B (en) Topical application of muscarinic analgesic drugs such as neostigmine
DE69918124D1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam